Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

DNA methylation: its role in cancer development and therapy.

Kurkjian C, Kummar S, Murgo AJ.

Curr Probl Cancer. 2008 Sep-Oct;32(5):187-235. doi: 10.1016/j.currproblcancer.2008.08.002. Review. No abstract available.

2.

Cancer prevention: epigenetics steps up to the plate.

Issa JP.

Cancer Prev Res (Phila). 2008 Sep;1(4):219-22. doi: 10.1158/1940-6207.CAPR-08-0029. Epub 2008 Mar 19. No abstract available.

3.

Myelodysplasia, megakaryocytes, and methylation.

Steensma DP.

Leuk Res. 2004 Aug;28(8):775-6. No abstract available.

PMID:
15203274
4.

Drug therapy for myelodysplastic syndrome: building evidence for action.

Tefferi A, Letendre L.

Cancer. 2006 Apr 15;106(8):1650-2. No abstract available.

5.

Targeting DNA methylation.

Issa JP, Kantarjian HM.

Clin Cancer Res. 2009 Jun 15;15(12):3938-46. doi: 10.1158/1078-0432.CCR-08-2783. Epub 2009 Jun 9.

6.

DNA methylation biomarkers in cancer: progress towards clinical implementation.

Mikeska T, Bock C, Do H, Dobrovic A.

Expert Rev Mol Diagn. 2012 Jun;12(5):473-87. doi: 10.1586/erm.12.45. Review.

PMID:
22702364
7.
8.

DNA methylation and gene silencing in cancer.

Baylin SB.

Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S4-11. Review.

PMID:
16341240
9.

[Demethylating medication in myelodysplastic syndrome].

Manson ML, Derissen EJ, Wijermans PW, Schellens JH, Beijnen JH.

Ned Tijdschr Geneeskd. 2012;156(4):A3167. Review. Dutch.

PMID:
22278034
10.

LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors.

Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D, Yoo C, Tannir N, Horne E, Groshen S, Jones P, Yang A, Issa JP.

Epigenetics. 2009 Apr 1;4(3):176-84. Epub 2009 Apr 6.

11.

Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.

Cowan LA, Talwar S, Yang AS.

Epigenomics. 2010 Feb;2(1):71-86. doi: 10.2217/epi.09.44. Review.

PMID:
22122748
12.

Decitabine and its role in the treatment of hematopoietic malignancies.

Plimack ER, Kantarjian HM, Issa JP.

Leuk Lymphoma. 2007 Aug;48(8):1472-81. Review.

PMID:
17701577
13.

Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndromes.

Carella AM.

Eur J Haematol. 2015 Jun;94(6):463. doi: 10.1111/ejh.12521. Epub 2015 Mar 16. No abstract available.

PMID:
25702976
16.

Decitabine is an effective treatment of idiopathic myelofibrosis.

Danilov AV, Relias V, Feeney DM, Miller KB.

Br J Haematol. 2009 Apr;145(1):131-2. doi: 10.1111/j.1365-2141.2008.07541.x. Epub 2008 Dec 26. No abstract available.

PMID:
19133981
17.

Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.

Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II.

Clin Cancer Res. 2009 Jun 1;15(11):3881-8. doi: 10.1158/1078-0432.CCR-08-2196. Epub 2009 May 26.

19.

GADD45 deregulation in cancer: frequently methylated tumor suppressors and potential therapeutic targets.

Zerbini LF, Libermann TA.

Clin Cancer Res. 2005 Sep 15;11(18):6409-13. No abstract available.

20.

Decitabine. MGI Pharma Inc/SuperGen Inc.

Arthur C.

IDrugs. 2004 Dec;7(12):1113-32. Review.

PMID:
15599805
Items per page

Supplemental Content

Write to the Help Desk